person · Reporting owner
PEI MELINDA LITHERLAND
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-RAD LABORATORIES, INC.BIO BIO.B · Entity 2247 | Director | April 21, 2026 | April 23, 2026 |
| RAPID MICRO BIOSYSTEMS, INC.RPID · Entity 6966 | Director | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-RAD LABORATORIES, INC.
Report date April 21, 2026 · Filed April 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Bio-Rad A Common StockSEC Table I · non-derivative | Direct | 715 |
Reported balance
After 2026-04-21 transaction · row 1
1 source rowRow 1 · 2026-04-21 · Exercise / conversion · Acquired 407 · Balance 715 F1: Shares of Class A common stock acquired on the vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 369 |
Reported balance
After 2026-04-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-21 · Grant · Acquired 369 · Balance 369 F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-04-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-21 · Exercise / conversion · Disposed 407 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Class A common stock acquired on the vesting of restricted stock units.
F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
F3: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders.
RAPID MICRO BIOSYSTEMS, INC.
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 100,687 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 12,787 · Balance 100,687 F1: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. |
| Series A Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2027-05-29 | Direct | 12,787 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Grant · Acquired 12,787 · Balance 12,787 F1: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F2: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise. |
| Series B Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.34 · Expires 2031-05-29 | Direct | 12,787 |
Reported balance
After 2026-05-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-29 · Grant · Acquired 12,787 · Balance 12,787 F1: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F2: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
F2: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2026 Filed Jun 2, 2026 23:44 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantSeries B Warrant (right to buy) · Derivative | 12,787 | $0.00 Strike: $2.34 | $0.00 |
DisclosureSEC source: 0001703469-26-000010 · wk-form4_1780443843.xml · derivative · entry 3 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,787 Underlying: Class A Common Stock · 12,787 shares Expires 2031-05-29 F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F1 · price: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F2 · derivative.exercise_date: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 23:44 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantSeries A Warrant (right to buy) · Derivative | 12,787 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001703469-26-000010 · wk-form4_1780443843.xml · derivative · entry 2 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,787 Underlying: Class A Common Stock · 12,787 shares Expires 2027-05-29 F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F1 · price: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F2 · derivative.exercise_date: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 23:44 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantClass A Common Stock | 12,787 | $1.96 | $24,998.59 |
DisclosureSEC source: 0001703469-26-000010 · wk-form4_1780443843.xml · nonDerivative · entry 1 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,687 F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 21, 2026 Filed May 26, 2026 23:25 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 38,700 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001703469-26-000007 · wk-form4_1779837928.xml · derivative · entry 2 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,700 Underlying: Class A Common Stock · 38,700 shares Expires 2036-05-20 F2 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| May 21, 2026 Filed May 26, 2026 23:25 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantClass A Common Stock | 19,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001703469-26-000007 · wk-form4_1779837928.xml · nonDerivative · entry 1 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,900 F1 · shares: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 19:25 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 407 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001703469-26-000002 · wk-form4_1776972330.xml · derivative · entry 3 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 407 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. F3 · derivative.expiration_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 19:25 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | GrantRestricted Stock Units · Derivative | 369 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001703469-26-000002 · wk-form4_1776972330.xml · derivative · entry 2 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 369 Underlying: Bio-Rad A Common Stock · 369 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. F3 · derivative.expiration_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 19:25 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 407 | $0.00 | $0.00 |
DisclosureSEC source: 0001703469-26-000002 · wk-form4_1776972330.xml · nonDerivative · entry 1 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| May 22, 2025 Filed May 28, 2025 00:12 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 28,650 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001380106-25-000133 · wk-form4_1748391137.xml · derivative · entry 2 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,650 Underlying: Class A Common Stock · 28,650 shares Expires 2035-05-21 F2 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| May 22, 2025 Filed May 28, 2025 00:12 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantClass A Common Stock | 14,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001380106-25-000133 · wk-form4_1748391137.xml · nonDerivative · entry 1 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,600 F1 · shares: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| April 22, 2025 Filed Apr 24, 2025 21:14 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 308 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-007907 · form4.xml · derivative · entry 3 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 308 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On September 6, 2024, the reporting person was granted 308 restricted stock units, vesting at 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. F4 · derivative.expiration_date: On September 6, 2024, the reporting person was granted 308 restricted stock units, vesting at 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. Read SEC document |
| April 22, 2025 Filed Apr 24, 2025 21:14 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | GrantRestricted Stock Units · Derivative | 407 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-007907 · form4.xml · derivative · entry 2 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 407 Underlying: Bio-Rad A Common Stock · 407 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. F3 · derivative.expiration_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. Read SEC document |
| April 22, 2025 Filed Apr 24, 2025 21:14 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 308 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-007907 · form4.xml · nonDerivative · entry 1 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| December 05, 2024 Filed Dec 5, 2024 23:44 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | PurchaseClass A Common Stock | 9,120 | $1.04 | $9,483.89 |
DisclosureSEC source: 0001380106-24-000210 · wk-form4_1733442280.xml · nonDerivative · entry 2 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,300 F1 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $1.03 to $1.04 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 23:44 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | PurchaseClass A Common Stock | 10,880 | $1.00 | $10,880.00 |
DisclosureSEC source: 0001380106-24-000210 · wk-form4_1733442280.xml · nonDerivative · entry 1 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,180 Read SEC document |
| November 27, 2024 Filed Nov 28, 2024 02:42 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | PurchaseClass A Common Stock | 19,892 | $1.05 | $20,886.60 |
DisclosureSEC source: 0001380106-24-000206 · wk-form4_1732761717.xml · nonDerivative · entry 2 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,300 Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 02:42 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | PurchaseClass A Common Stock | 108 | $1.04 | $112.32 |
DisclosureSEC source: 0001380106-24-000206 · wk-form4_1732761717.xml · nonDerivative · entry 1 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,408 Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 17:53 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 308 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016372 · form4.xml · derivative · entry 1 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308 Underlying: Bio-Rad A Common Stock · 308 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. Read SEC document |
| May 23, 2024 Filed May 28, 2024 23:05 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 28,650 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001380106-24-000146 · wk-form4_1716937514.xml · derivative · entry 2 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,650 Underlying: Class A Common Stock · 28,650 shares Expires 2034-05-22 F2 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| May 23, 2024 Filed May 28, 2024 23:05 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantClass A Common Stock | 14,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001380106-24-000146 · wk-form4_1716937514.xml · nonDerivative · entry 1 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,300 F1 · shares: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| May 04, 2023 Filed May 5, 2023 22:05 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001380106-23-000081 · wf-form4_168332432591707.xml · derivative · entry 1 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2033-05-03 F1 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| May 23, 2022 Filed Jun 10, 2022 22:27 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001127602-22-017264 · form4.xml · derivative · entry 1 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Class A Common Stock · 12,500 shares Expires 2032-05-22 F1 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 00:03 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001104659-21-092761 · tm2122156-17_4seq1.xml · derivative · entry 1 PEI MELINDA LITHERLAND · CIK 0001703469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2031-07-13 F1 · derivative.exercise_date: This option vests and becomes exercisable, subject to the Reporting Person's continued service to the Issuer's Board, in 36 substantially equal monthly installments with the first installment vesting on August 14, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.